Skip to content
Head to head

Legend Biotech vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: LEGN · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

LEGN -48.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
LEGNVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price15.25515.02
Change today-5.28%-1.08%
1-year return-44.6%+22.0%
Market cap$2.96B$130.58B
52-week range15.15 – 37.50412.27 – 568.67
Valuation
P/E (TTM)-762.5033.14
P/E percentile, own 5-yr range0th99th
P/B2.336.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.6215.32
Net profit (TTM)$-314.23M$3.88B
Revenue (TTM)$1.36B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+32.0%+11.8%
Gross margin57.0%85.5%
Operating margin2.6%33.1%
Net margin-0.0%30.7%
Free cash flow (TTM)$-187.10M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.7%96.8%
Insider activity (12mo)0 buy / 41 sell28 buy / 22 sell
Short interest (% of float)6.1%1.9%
Analyst consensus60% buy / 40% hold (10)95% buy / 5% hold (21)
Analyst price target$42 (+175%)$624 (+21%)
StockVane view
StockVane Quant RatingE (8)C (68)
Company
Employees2,9006,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.